Boston Scientific Co. (NYSE:BSX) Stock Holdings Boosted by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its position in Boston Scientific Co. (NYSE:BSX) by 8.9% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,047,661 shares of the medical equipment provider’s stock after purchasing an additional 411,628 shares during the quarter. Dimensional Fund Advisors LP owned about 0.34% of Boston Scientific worth $388,724,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BSX. CVA Family Office LLC raised its holdings in shares of Boston Scientific by 7.4% during the second quarter. CVA Family Office LLC now owns 1,909 shares of the medical equipment provider’s stock valued at $147,000 after buying an additional 131 shares during the last quarter. International Assets Investment Management LLC raised its stake in Boston Scientific by 0.6% during the 2nd quarter. International Assets Investment Management LLC now owns 22,596 shares of the medical equipment provider’s stock valued at $1,740,000 after acquiring an additional 139 shares in the last quarter. ST Germain D J Co. Inc. boosted its position in Boston Scientific by 8.0% during the 2nd quarter. ST Germain D J Co. Inc. now owns 1,923 shares of the medical equipment provider’s stock worth $148,000 after acquiring an additional 143 shares during the period. Pinnacle Associates Ltd. grew its stake in shares of Boston Scientific by 2.0% in the first quarter. Pinnacle Associates Ltd. now owns 7,478 shares of the medical equipment provider’s stock worth $512,000 after purchasing an additional 148 shares in the last quarter. Finally, Transcend Capital Advisors LLC increased its holdings in shares of Boston Scientific by 2.2% during the second quarter. Transcend Capital Advisors LLC now owns 6,773 shares of the medical equipment provider’s stock valued at $522,000 after purchasing an additional 148 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total transaction of $570,511.10. Following the transaction, the executive vice president now directly owns 37,468 shares of the company’s stock, valued at $3,061,135.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 20,949 shares of company stock valued at $1,627,877 in the last 90 days. 0.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

BSX has been the subject of several research analyst reports. Needham & Company LLC upped their price objective on shares of Boston Scientific from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. TD Cowen upped their price target on shares of Boston Scientific from $77.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Canaccord Genuity Group raised their price objective on shares of Boston Scientific from $83.00 to $88.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Raymond James upped their target price on Boston Scientific from $91.00 to $94.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, September 4th. Finally, BTIG Research increased their price target on Boston Scientific from $80.00 to $84.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Three analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $85.38.

Boston Scientific Trading Up 0.2 %

Boston Scientific stock opened at $83.51 on Tuesday. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $84.11. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. The firm has a market capitalization of $122.52 billion, a price-to-earnings ratio of 70.18, a P/E/G ratio of 2.75 and a beta of 0.79. The company has a 50 day moving average price of $78.23 and a 200 day moving average price of $74.28.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, topping the consensus estimate of $0.58 by $0.04. The business had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. Boston Scientific’s revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.53 earnings per share. Research analysts forecast that Boston Scientific Co. will post 2.4 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.